Complete Guide to Donidalorsen Pharmacokinetics
Overview
Donidalorsen is a ASO used in the Rare Disease therapeutic area. It is indicated for Hereditary Angioedema. PK/PD simulator for donidalorsen antisense oligonucleotide in hereditary angioedema. Explore prekallikrein knockdown dynamics.
Mechanism of Action
Donidalorsen exerts its pharmacological effect by targeting KLKB1/Prekallikrein. As a ASO, it modulates this target to achieve therapeutic efficacy in Hereditary Angioedema. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PK/PD models for Donidalorsen:
| Parameter | Value |
|---|---|
| ka | 0.952 h-1 |
| Q F | 2.58 L/h |
| CL F | 12.8 L/h |
| IC50 | 0.158 ng/mL |
| Imax | 0.992 |
| Vc F | 69.8 L |
| Vp F | 1840 L |
| kout | 0.00266 h-1 |
| BL PKK | 139 mg/L |
| half life | 31.4 days |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Donidalorsen is administered via the SC route. Subcutaneous administration provides sustained absorption from the injection site. Bioavailability and absorption rate may vary by injection site and volume.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Rare Disease therapeutic area, for the treatment of Hereditary Angioedema, understanding the pharmacokinetics of Donidalorsen is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Donidalorsen pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Donidalorsen PK Simulator
Explore Donidalorsen pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Donidalorsen?
The elimination half-life of Donidalorsen depends on patient-specific factors. Based on published models, the typical half-life is approximately 31.4 days.
How is Donidalorsen administered?
Donidalorsen is administered via the SC route. It is indicated for Hereditary Angioedema. As a ASO, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Donidalorsen?
Key pharmacokinetic parameters for Donidalorsen include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Donidalorsen dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Donidalorsen PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.